Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00077350 · ClinicalTrials.gov registry record · Phase 2

A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer

A Phase 2 study of Recurrent Non-small Cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT00077350 is a Phase 2 study of Recurrent Non-small Cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants, below the 144-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00077350, a Phase 2 study of Recurrent Non-small Cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving 3-AP together with gemcitabine may kill more tumor cells. This phase II trial is studying how well giving 3-AP together with gemcitabine works as second-line therapy in treating patients with progressive or recurrent non-small cell lung cancer

Conditions Studied

Recurrent Non-small Cell Lung Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG gemcitabine hydrochloride
  • DRUG triapine

Study Locations (1)

Massachusetts

  • Eastern Cooperative Oncology Group - Boston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2004-07
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00077350

The ClinicalTrials.gov registry entry for NCT00077350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 15 other Recurrent Non-small Cell Lung Cancer trials with a reported enrollment target (67% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Recurrent Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.

NCT00077350 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00077350 about?

NCT00077350 is a clinical study titled "A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer". Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving 3-AP together with gemcitabine may kill more tumor cells. This phase II trial is studying how well giving 3-AP together with gemcitabine works as sec...

What is the current status of trial NCT00077350?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-07.

What conditions does trial NCT00077350 study?

This clinical trial studies the following conditions: Recurrent Non-small Cell Lung Cancer.

What interventions are being tested in trial NCT00077350?

The interventions under investigation include: laboratory biomarker analysis (OTHER), gemcitabine hydrochloride (DRUG), triapine (DRUG).

Who is sponsoring clinical trial NCT00077350?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00077350 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Non-small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Non-small Cell Lung Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.